ENDOMETRIAL CANCER

This study tested a combination of two drugs, copanlisib and fulvestrant, in people with advanced hormone receptor-positive (ER+ and/or PR+) cancers of the ovary, endometrium, or breast that also have certain genetic changes (PI3K/PTEN). Only 7 people took part before the study w…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-phase study tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours (like breast, ovarian, or head and neck cancers) that had stopped responding to standard treatments. The drug uses a radioactive particle attached …

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

This study aimed to see if taking letrozole (a hormone therapy) after standard treatment could help prevent endometrial cancer from coming back in patients with a non-specific molecular profile. The trial was stopped early after enrolling only 12 participants, so no firm conclusi…

This early-phase study tested an experimental oral drug, NKT3447, in 23 adults with advanced or metastatic solid tumors (including ovarian, endometrial, gastric, lung, and breast cancers) that had stopped responding to standard treatments. The main goals were to check safety, fin…

This study tested a new drug, BLU-222, for people with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if it could shrink tumors. The study was ended early, so results are limited.

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors like ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…

This study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women with a certain type of recurrent endometrial cancer. Only 4 participants were enrolled before the study was stopped early. The goal was to measure how many pati…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested whether a newer, more precise radiation method called IMRT could reduce bowel and bladder side effects compared to standard 3D radiation in women who had surgery for high-risk endometrial cancer. About 92 participants were planned. The trial was stopped early, b…

This early-stage study aimed to see how ceralasertib, an experimental cancer drug, affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no meaningful conclus…